Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02797470 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv23
  2. Study completion date: Jun 30, 2025 to Mar 2036v22
  3. Re-verified, no change to tracked fieldsv21
  4. Primary completion date: Jan 27, 2023 to May 13, 2021
    • Eligibility criteria revised
    v20
  5. Results first posted: Jul 20, 2023
    • Primary endpoint revised
    • Secondary endpoints revised (16)
    v19
Show 17 earlier versionsHide 17 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 18 to confirmed 11
    • Primary completion date changed from estimate of Dec 31, 2024 to Jan 27, 2023
    • Site details revised at 4 of 4 sites
    v18
  2. Site details revised at 1 of 4 sitesv17
  3. Study description expanded, about 463 wordsv16
  4. Eligibility criteria revised
    • Secondary endpoints: details revised at 5 of 16 entries
    v15
  5. Primary completion date: Sep 30, 2022 to Dec 31, 2024v14 Show 5 more changesShow less
    • Primary endpoints: 2 to 1
    • Study completion date: Sep 30, 2024 to Jun 30, 2025
    • Eligibility criteria expanded, about 238 words
    • Secondary endpoints revised (16)
    • Study description shortened, about 391 words
  6. Primary completion date: Sep 2022 to Sep 30, 2022
    • Study completion date: Sep 2024 to Sep 30, 2024
    • Start date: May 2016 to Jun 23, 2016
    • Secondary endpoints revised (16)
    v13
  7. Primary completion date: Sep 2021 to Sep 2022
    • Study completion date: Jun 2036 to Sep 2024
    v12
  8. Site contacts updated at 1 of 4 sitesv11
  9. Site contacts updated at 1 of 4 sitesv10
  10. Primary completion date: Sep 2019 to Sep 2021
    • Study completion date: Jun 2034 to Jun 2036
    • Study sites revised (4)
    v9
  11. Site contacts updated at 1 of 4 sitesv8
  12. Study sites revised (4)v7
  13. Collaborators: 1 to 2v6
  14. Site details revised at 1 of 4 sitesv5
  15. Trial status: Suspended to Recruiting
    • Study completion date: Jun 2034
    • Site details revised at 4 of 4 sites
    v4
  16. Trial status: Recruiting to Suspended Sponsor's reason: Temporarily suspended due to manufacturing issues
    • Site details revised at 4 of 4 sites
    v3
  17. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AIDS Malignancy Consortium
19 trials monitored
See 1 trial at risk
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
DLBCL
703 trials monitored
See 44 trials at risk
Follicular Lymphoma
347 trials monitored
See 28 trials at risk
and 2 more diseases
This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. In gene therapy, small stretches of deoxyribonucleic acid (DNA) called "anti-HIV genes" are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.
Trial Details
NCT Number NCT02797470
Lead Sponsor AIDS Malignancy Consortium
Collaborators: National Cancer Institute (NCI), California Institute for Regenerative Medicine (CIRM)
Conditions
(from sponsor)		 HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma +3 more
Related terms Burkitt Lymphoma, HIV Infections, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Plasmablastic Lymphoma
Enrollment 11 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov